Philadelphia – September 22, 2026 -- Health Union and DTC Perspectives have launched a strategic partnership to stage an invitation-only executive summit focused on redefining commercial models for rare disease and niche oncology marketing.
Summit convenes senior biopharma marketers in Boston on November 5, 2026
The Rare Marketing Summit: Redefining the Commercial Model for Rare Disease will run from 10:00 AM to 4:00 PM at The Westin Copley Place in Boston, MA, followed by a cocktail reception. Attendance is capped to preserve intimate peer exchange among senior-level biopharma marketing leaders.
Six topic tracks target ultra-small patient populations and generalist HCP activation
The agenda covers diagnostic acceleration, evolving FDA risk-disclosure standards, AI targeting and CTV channel expansion for micro-audiences, high-touch patient and caregiver journeys, generalist physician symptom recognition, and advocacy partnerships with non-profit and patient support networks.
Health Union CEO cites need to depart from mass-market pharma playbooks
"Commercializing a rare disease therapy requires a fundamental departure from mass-market pharma strategies," said Olivier Chateau, Co-Founder and CEO of Health Union. Bob Ehrlich, CEO of DTC Perspectives, said the collaboration creates a peer-to-peer environment to exchange approaches on AI targeting, non-specialist HCP engagement, and advocacy alignment.
Partnership extends to a Rare Disease Workshop and Awards Ceremony in June 2027
Health Union and DTC Perspectives plan to expand the initiative with a dedicated workshop and awards ceremony in June 2027, positioned as an official extension of the annual DTC National Conference. Invited biopharma leaders can request registration details through DTC Perspectives.